The role of soluble immune checkpoint molecules in hematologic malignancies (review)

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Introduction. Immune checkpoint (IC) signaling pathways are involved in regulating the functions of T lymphocytes and NK cells, which play a key role in antitumor and antiviral control.

The purpose of our study was to systematically analyze the information presented in current literature on the role of soluble ICs (sICs) in the development of hematological neoplasia.

Material and methods. The review includes data from foreign and domestic articles published in PubMed over the past 15 years, which are devoted to the role of soluble IC molecules in the pathogenesis of hematologic malignancies.

Results. The development of lymphoid and myeloid neoplasia is accompanied by an increase in the level of a number of soluble immunoregulatory molecules (programmed cell death protein 1 (sPD-1) and its ligands sPD-L1 and sPD-L2, cytotoxic lymphocyte antigen 4 (sCTLA-4), T-cell immunoglobulin domain and mucin domain 3 (sTIM-3), costimulatory molecules sCD86, sCD40), which is associated with a poor prognosis, shorter overall and progression-free survival of patients. The established patterns confirm the pathogenetic role of the listed soluble IC molecules in the development of malignant diseases of the blood system, as well as their significance as predictors of response to therapy and risk groups stratification.

Conclusion. The presented analysis demonstrates the significant pathogenetic and prognostic role of sICs in hematological neoplasia of lymphoid and myeloid nature.

全文:

受限制的访问

作者简介

Tatyana Glazanova

Russian Research Institute of Hematology and Transfusiology

编辑信件的主要联系方式.
Email: tatyana-glazanova@yandex.ru
ORCID iD: 0000-0002-1022-8127

Chief researcher, Doctor of medical sciences

俄罗斯联邦, 2-aya Sovetskaya, 16, Saint-Petersburg, 191024

Irina Pavlova

Russian Research Institute of Hematology and Transfusiology

Email: pavlova@niigt.ru
ORCID iD: 0000-0001-7756-4902

Chief researcher, Doctor of medical sciences

俄罗斯联邦, 2-aya Sovetskaya, 16, Saint-Petersburg, 191024

Elena Kuzmich

Russian Research Institute of Hematology and Transfusiology

Email: yelenakuzmich@gmail.com
ORCID iD: 0000-0003-0489-1763

Leading researcher, Candidate of biological sciences

俄罗斯联邦, 2-aya Sovetskaya, 16, Saint-Petersburg, 191024

Nikolay Kushlinskii

N.N. Blokhin Russian Cancer Research Center of the RAMS

Email: kne3108@gmail.com
ORCID iD: 0000-0002-3898-4127

Scientific director of the laboratory, Doctor of medical sciences, Professor, RAS Academician

俄罗斯联邦, Kashirskoe shosse, 24, Moscow, 115478

参考

  1. Рукавицын О.А. Гематология. Национальное руководство, 2-е издание. М.: ГЭОТАР-Медиа, 2024; 920. [Rukavitsyn O.A. Hematology. National Guide, 2nd edition. GEOTAR-Media, 2024; 920 (in Russian)].
  2. Rau F.C., Dieter J., Luo Z., Priest S., Baumgarth N. B7-1/2 (CD80/CD86) direct signaling to B cells enhances IgG secretion. J. Immunol. 2009; 183 (12): 7661–71. doi: 10.4049/jimmunol.0803783
  3. Hock B., Patton W.N., Budhia S., Mannari D., Roberts P., McKenzie J.L. Human plasma contains a soluble form of CD86 which is present at elevated levels in some leukaemia patients. Leukemia. 2002; 16 (5): 865–73. https://doi.org/10.1038/sj.leu.2402466
  4. Contin C., Pitard V., Delmas Y., Pelletier N., Defrance T., Moreau J.-F., Merville P., Déchanet-Merville J. Potential role of soluble CD40 in the humoral immune response impairment of uraemic patients. Immonology. 2003; 110: 131–40. https://doi.org/10.1046/j.1365-2567.2003.01716.x)
  5. Wagner A.H., Klersy A., Sultan C.S., Hecker M. Potential role of soluble CD40 receptor in chronic inflammatory diseases. Biochemical Pharmacology. 2023; 217: 115858. https://doi.org/10.1016/j.bcp.2023.115858
  6. Hock B., McKenzie J.L., Patton N.W., Drayson M., Taylor K., Wakeman C. Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies. Cancer. 2006; 106 (10): 2148–57. doi: 10.1002/cncr.21816
  7. Landeira-Viñuela A., Arias-Hidalgo C., Juanes-Velasco P., Alcoceba M., Navarro-Bailón A., Pedreira C., Lecrevisse Q., Diaz-Muñoz L., Sánchez-Santos J., Hernández A., Garcia-Vaquero M., Góngora R., De Las Rivas J., González M., Orfao A., Fuentes M. Unravelling soluble immune checkpoints in chronic lymphocytic leukemia: Physiological immunomodulators or immune dysfunction. Front. Immunol. 2022; 13. doi: 10.3389/fimmu.2022.965905
  8. Mortensen J., Hansen I.M., Clausen M.R., Bjerre M., Amore F. Elevated Pre-Therapeutic Serum Levels of Soluble Programmed Death 1 Protein (sPD-1) Identify DLBCL Patients with Adverse Prognostic Features. Blood. 2017; 130 (1): 4148. doi: 10.1182/blood.V130.Suppl_1.4148.4148
  9. Rossille D., Gressier M., Damotte D., Maucort-Boulch D., Pangault C., Semana G., Le Gouill S., Haioun C., Tarte K., Lamy T., Milpied N., Fest T. High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-cell lymphoma: results from a French multicenter clinical trial. Leukemia. 2014; 28 (12): 2367–75. doi: 10.1038/leu.2014.137.
  10. Vajavaara H., Mortensen J.B., Leivonen S.K., Hansen I.M., Ludvigsen M., Holte H., Jørgensen J., Bjerre M., d’Amore F., Leppä S. Soluble PD-1 But not PD-L1 Levels Predict Poor Outcome in Patients With High-Risk Diffuse Large B-Cell Lymphoma. Cancers (Basel). 2021; 13 (3): 398. doi: 10.3390/cancers13030398
  11. El-Ghammaz A., Gadallah H.A., Kamal G., Maher M.M., Mohamad M.A. Impact of serum soluble programed death ligand 1 on end of treatment metabolic response of diffuse large B cell lymphoma patients. Clin Exp Med. 2018; 18: 505–12. doi: 10.1007/s10238-018-0506-5
  12. Mortensen J., Monrad I., Enemark M., Ludvigsen M., Kamper P., Bjerre M., d’Amore F. Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies. Eur J. Haematol. 2021; 107 (1): 81–91. doi: 10.1111/ejh.13621
  13. Ask E.H., Tschan-Plessl A., Gjerdingen T.J., Sætersmoen M.L., Hoel H.J., Wiiger M.T., Olweus J., Wahlin B., Lingjærde O.C., Horowitz A., Cashen A., Watkins M., Fehniger T., Holte H., Kolstad A., Malmberg K.-J. A Systemic Protein Deviation Score Linked to PD-1+ CD8+ T Cell Expansion That Predicts Overall Survival in Diffuse Large B Cell Lymphoma. Clinical and translational article. 2021; 2 (2): 180–95. E5. https://doi.org/10.1016/j.medj.2020.10.006
  14. Iguchi-Manaka A., Okumura G., Kojima H., Cho Y., Hirochika R., Bando H., Sato T., Yoshikawa H., Hara H., Shibuya A., Shibuya K. Increased Soluble CD155 in the Serum of Cancer Patients. PLoS ONE. 2016; 11 (4): e0152982. https://doi.org/10.1371/journal.pone.0152982
  15. Azzazi M., Hegab H., El-Ghammaz A., Saber H., Afifi Y. Impact of serum soluble CD155 level at diagnosis on interim response to CHOP with or without rituximab in diffuse large B cell lymphoma. Clin Exp Med. 2022; 22: 173–81. https://doi.org/10.1007/s10238-021-00741-9
  16. Guo X., Wang J., Jin J., Chen H., Zhen Z., Jiang W., Lin T., Huang H., Xia Z., Sun X. High serum level of soluble programmed death ligand 1 is associated with a poor prognosis in Hodgkin lymphoma. Transl Oncol. 2018; 11 (3): 779–85. doi: 10.1016/j.tranon.2018.03.012
  17. Бессмельцев С.С., Сидоркевич С.В. Федеральное руководство по гематологии. М.: СИМК, 2024; 2: 572. [Bessmeltsev S.S., Sidorkevich S.V. Federal Guide to Hematology. M: SIMK, 2024; 2: 572 (in Russian)]
  18. Hock B., Drayson M., Patton W.N., Taylor K., Kerr L., McKenzie J.L. Circulating levels and clinical significance of soluble CD86 in myeloma patients. Br. J. Haematol. 2006; 133: 165–72.
  19. Ishibashi M., Kinoshita R., Inokuchi K., Handa H., Sasaki M., Komatsu N., Imai Y., Hiroike N., Tanaka J., Tanosaki S., Ito S., Sunakawa M., Asayama T., Kuribayashi-hamada Y., Morita R., Tamura H. Serum soluble CD86, still a prognostic factor in the novel agent era in multiple myeloma patients, is produced by myeloma cells with high CD86 variant 3 expression. 2019. Blood. 2019; 134 (1): 436.1 https://doi.org/10.1182/blood-2019-124635
  20. Kinoshita R., Ishibashi M., Handa H., Sasaki M., Imai Y., Tanaka N., Ito S., Sunakawa M., Kaito Y., Asayama T., Komatsu N., Tanaka J., Odajima T., Sugimori H., Yamaguchi H., Inokuchi K., Tamura H. The levels of serum soluble CD86 are correlated with the expression of CD86 variant 3 gene and are prognostic indicators in patients with myeloma. Experimental Hematology. 2023; 121: 38–47. E2. https://doi.org/10.1016/j.exphem.2023.01.006
  21. Wang L., Wang H., Chen H., Wang W.D., Chen X.Q., Geng Q.R., Xia Z.J., Lu Y. Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma. Oncotarget. 2015; 6 (38): 41228–36. doi: 10.18632/oncotarget.5682
  22. Huang S.Y., Lin H.H., Lin C.-W., Li C.C., Yao M., Tang J.L., Hou H.A., Tsay W., Chou S.J., Cheng C.L., Tien H.F. Soluble PD-L1: a biomarker to predict progression of autologous transplantation in patients with multiple myeloma. Oncotarget. 2016; 7 (38): 62490–502. doi: 10.18632/oncotarget.11519
  23. Ho A.W., Leleu X., Hatjiharissi E., Tournilhac O., Xu L., O’Connor K., Manning R., Santos D., Chemaly M., Branagan A., Hunter Z., Patterson C., Anderson K., Treon S. A novel functional role for soluble CD27 in the pathogenesis of Waldenstrom’s Macroglobulinemia. Blood. 2005; 106 (11): 4701. https://doi.org/10.1182/blood.V106.11.4701.4701
  24. Hargreaves P., Al-Shamkhani А. Soluble CD30 binds to CD153 with high affinity and blocks transmembrane signaling by CD30. Eur J. Immunol. 2002; 32 (1): 163–73. doi: 10.1002/1521-4141(200201)32:1
  25. Pornkuna R., Nishioka C., Takemoto S. What is the Role of Soluble Cytokine Receptors in Adult T-cell Leukemia/Lymphoma? J Hematol Thrombo Dis. 2014; 2 (5): 1000154. doi: 10.4172/2329-8790.1000154
  26. Shigeki T. Possible stimulatory immune checkpoint molecules releasing allows adult T-cell leukemia/lymphoma development. Annals of Oncology. 2016; 27 (7): VII85. https://doi.org/10.1093/annonc/mdw521.046
  27. Wang H., Wang L., Liu W.-J., Xia Z.-J., Huang H.-Q., Jiang W.-Q., Li Z.-M., Lu Y. High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients. Oncotarget. 2016; 7 (22): 33035–45. doi: 10.18632/oncotarget.8847
  28. Ward F., Dahal L.N., Wijesekera S.K., Abdul-Jawad S.K., Kaewarpai T., Xu H., Vickers M.A., Barker R.N.. The soluble isoform of CTLA-4 as a regulator of T-cell responses. Eur J. Immunol. 2013; 43 (5): 1274–85. doi: 10.1002/eji.201242529
  29. Ward F., Dahal L.N., Khanolkar R.C., Shankar S.P., Barker R.N. Targeting the alternatively spliced soluble isoform of CTLA-4: prospects for immunotherapy? Immunotherapy. 2014; 6 (10): 1073–84. doi: 10.2217/imt.14.73
  30. Hayashi H., Chamoto K., Hatae R., Kurosaki T., Togashi Y., Fukuoka K., Goto M., Chiba Y., Tomida S., Ota T., Haratani K., Takahama T., Tanizaki J., Yoshida T., Iwasa T., Tanaka K., Takeda M., Hirano T., Yoshida H., Ozasa H., Sakamori Y., Sakai K., Higuchi K., Uga H., Suminaka C., Hirai T., Nishio K., Nakagawa K., Honjo T. Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade. The Journal of Clinical Investigation. 2024; 134 (7): e168318. https://doi.org/10.1172/JCI168318
  31. Sun T., Hu Z., Shen H., Lin D. Genetic polymorphisms in cytotoxic T-lymphocyte antigen 4 and cancer: the dialectical nature of subtle human immune dysregulation. Cancer Res. 2009; 69: 6011–4. doi: 10.1158/0008-5472.CAN-09-0176
  32. Simone R., Tenca C., Fais F., Luciani M., De Rossi G., Pesce G., Bagnasco M., Saverino D. A soluble form of CTLA-4 is present in paediatric patients with acute lymphoblastic leukaemia and correlates with CD1d+ expression. PLoS One. 2012; 7 (9): e44654 https://doi.org/10.1371/journal.pone.0044654
  33. Fais F., Tenca C., Cimino G., Coletti V., Zanardi S., Bagnara D., Saverino D., Zarcone D., De Rossi G., Ciccone E., Grossi C.E. CD1d expression on B-precursor acute lymphoblastic leukemia subsets with poor prognosis. Leukemia. 2005; 19 (4): 551–6. doi: 10.1038/sj.leu.2403671
  34. Бессмельцев С.С., Сидоркевич С.В. Федеральное руководство по гематологии. М.: СИМК, 2024; 1: 572. [Bessmeltsev S.S., Sidorkevich S.V. Federal Guide to Hematology. M: SIMK, 2024; 1: 572 (in Russian)]
  35. Kikushige Y., Miyamoto T., Yuda J., Jabbarzadeh-Tabrizi S., Shima T., Takayanagi S., Niiro H., Yurino A., Miyawaki K., Takenaka K., Iwasaki H., Akashi K. A TIM-3/Gal-9 autocrine stimulatory loop drives self-renewal of human myeloid leukemia stem cells and leukemic progression. Cell Stem Cell. 2015; 17 (3): 341–52. doi: 10.1016/j.stem.2015.07.011
  36. Bailly C., Thuru X., Goossens L., Goossens J.F. Biochemical Soluble TIM-3 as a biomarker of progression and therapeutic response in cancers and other of human diseases. Pharmacology. 2023; 209: 115445. doi: 10.1016/j.bcp.2023.115445
  37. Gonçalves Silva I., Yasinska I., Sakhnevych S., Fiedler W., Wellbrock J., Bardelli M., Varani L., Hussain R., Siligardi G., Ceccone G., Berger S., Ushkaryov Y., Gibbs B., Fasler-Kan E., Sumbayev V. The Tim-3-galectin-9 secretory pathway is involved in the immune escape of human acute myeloid leukemia cells. EBioMedicine. 2017; 22: 44–57. https://doi.org/10.1016/j.ebiom.2017.07.018
  38. Hock B., McKenzie J., Patton W., Haring L., Yang Y., Shen Y. The clinical significance of soluble CD86 levels in patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer. 2003; 98 (8): 1681–8. https://doi.org/10.1002/cncr.11693
  39. Aref S., El Agdar M., El Sebaie A., Abouzeid T., Sabry M., Ibrahim L. Prognostic Value of CD200 Expression and Soluble CTLA-4 Concentrations in Intermediate and High-Risk Myelodysplastic Syndrome Patients. Asian Pacific J. of Cancer Prevention. 2020; 21: 2225–30. doi: 10.31557/APJCP.2020.21.8.2225

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Russkiy Vrach Publishing House, 2024